Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone

M. Mahdal, T. Tomáš, V. Apostolopoulos, D. Adámková, P. Múdry, I. Staniczková Zambo, L. Pazourek

. 2023 ; 15 (18) : . [pub] 20230921

Status not-indexed Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23015237

Grant support
NU22-10-00054 Ministry of Healthcare of the Czech Republic

Giant cell tumour of bone (GCTB) is one of the most common local aggressive tumourous lesions with a wide variety of biological behaviour. However, there are no clear indicative criteria when choosing the type of procedure and the complication rates remain high, especially in terms of local recurrence. The purpose of the study was to (1) identify the main risk factors for local recurrence, (2) evaluate the recurrence-free survival in dependence on neoadjuvant denosumab use and the type of procedure, and (3) compare the functional outcomes after curettage and en bloc resection. The group included 102 patients with GCTB treated between 2006 and 2020. The mean age of patients was 34.4 years (15-79). The follow-up period was 8.32 years (2-16) on average. Local recurrence occurred in 14 patients (29.8%) who underwent curettage and in 5 patients (10.6%) after en bloc resection. Curettage was shown to be a factor in increasing recurrence rates (OR = 3.64 [95% CI: 1.19-11.15]; p = 0.023). Tibial location was an independent risk factor for local recurrence regardless of the type of surgery (OR = 3.22 [95% CI: 1.09-9.48]; p = 0.026). The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments at five years postoperatively (p = 0.0307). Functional ability and pain as reported by patients at the latest follow-up were superior after curettage compared to resection for upper and lower extremity (mean difference: -4.00 [95% CI: -6.81 to -1.18]; p < 0.001 and mean difference: -5.36 [95% CI: -3.74 to -6.97]; p < 0.001, respectively). Proximal tibia tumour location and curettage were shown to be major risk factors for local recurrence in GCTB regardless of neoadjuvant denosumab treatment. The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments. The functional outcome of patients after curettage was better compared to en bloc resection.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23015237
003      
CZ-PrNML
005      
20240206085617.0
007      
ta
008      
231010s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers15184664 $2 doi
035    __
$a (PubMed)37760632
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Mahdal, Michal $u First Department of Orthopaedic Surgery, St. Anne's University Hospital, 60200 Brno, Czech Republic $u Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic $1 https://orcid.org/0000000221369136
245    10
$a Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone / $c M. Mahdal, T. Tomáš, V. Apostolopoulos, D. Adámková, P. Múdry, I. Staniczková Zambo, L. Pazourek
520    9_
$a Giant cell tumour of bone (GCTB) is one of the most common local aggressive tumourous lesions with a wide variety of biological behaviour. However, there are no clear indicative criteria when choosing the type of procedure and the complication rates remain high, especially in terms of local recurrence. The purpose of the study was to (1) identify the main risk factors for local recurrence, (2) evaluate the recurrence-free survival in dependence on neoadjuvant denosumab use and the type of procedure, and (3) compare the functional outcomes after curettage and en bloc resection. The group included 102 patients with GCTB treated between 2006 and 2020. The mean age of patients was 34.4 years (15-79). The follow-up period was 8.32 years (2-16) on average. Local recurrence occurred in 14 patients (29.8%) who underwent curettage and in 5 patients (10.6%) after en bloc resection. Curettage was shown to be a factor in increasing recurrence rates (OR = 3.64 [95% CI: 1.19-11.15]; p = 0.023). Tibial location was an independent risk factor for local recurrence regardless of the type of surgery (OR = 3.22 [95% CI: 1.09-9.48]; p = 0.026). The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments at five years postoperatively (p = 0.0307). Functional ability and pain as reported by patients at the latest follow-up were superior after curettage compared to resection for upper and lower extremity (mean difference: -4.00 [95% CI: -6.81 to -1.18]; p < 0.001 and mean difference: -5.36 [95% CI: -3.74 to -6.97]; p < 0.001, respectively). Proximal tibia tumour location and curettage were shown to be major risk factors for local recurrence in GCTB regardless of neoadjuvant denosumab treatment. The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments. The functional outcome of patients after curettage was better compared to en bloc resection.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Tomáš, Tomáš $u First Department of Orthopaedic Surgery, St. Anne's University Hospital, 60200 Brno, Czech Republic $u Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic
700    1_
$a Apostolopoulos, Vasileios $u First Department of Orthopaedic Surgery, St. Anne's University Hospital, 60200 Brno, Czech Republic $u Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic $1 https://orcid.org/0000000197194769
700    1_
$a Adámková Krákorová, Dagmar $u Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic $u Clinic of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 60200 Brno, Czech Republic $7 xx0084127
700    1_
$a Múdry, Peter $u Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic $u Department of Pediatric Oncology, University Hospital Brno, 66263 Brno, Czech Republic $1 https://orcid.org/0000000334347937
700    1_
$a Staniczková Zambo, Iva $u Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic $u First Department of Pathology, St. Anne's University Hospital, 60200 Brno, Czech Republic $1 https://orcid.org/0000000211890702
700    1_
$a Pazourek, Lukáš $u First Department of Orthopaedic Surgery, St. Anne's University Hospital, 60200 Brno, Czech Republic $u Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic $1 https://orcid.org/0000000315351842
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 15, č. 18 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37760632 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231010 $b ABA008
991    __
$a 20240206085614 $b ABA008
999    __
$a ok $b bmc $g 1997060 $s 1201599
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 15 $c 18 $e 20230921 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a NU22-10-00054 $p Ministry of Healthcare of the Czech Republic
LZP    __
$a Pubmed-20231010

Find record

Citation metrics

Archiving options